Pneumothorax in connective tissue disease-associated interstitial lung disease

PLoS One. 2020 Jul 7;15(7):e0235624. doi: 10.1371/journal.pone.0235624. eCollection 2020.

Abstract

Background: Spontaneous pneumothorax is a complication that occurs in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD); however, few studies on the clinical implications of pneumothorax for patients with CTD-ILD have been performed.

Objectives: This study aimed to investigate the incidence and prognostic significance of pneumothorax and the risk factors for its onset in patients with CTD-ILD.

Methods: This study included 140 consecutive patients with CTD-ILD. Clinical characteristics, laboratory findings, pulmonary function test results, and chest high-resolution computed tomography (HRCT) images were retrospectively evaluated.

Results: A total of 18 patients (12.9%) developed pneumothorax during their clinical course. The cumulative incidence of pneumothorax from the time of CTD-ILD diagnosis was 6.5%, 8.7%, and 11.3% at 1, 3, and 5 years, respectively. The 10-year survival rate was significantly lower in patients with pneumothorax (29.6%) than that in those without pneumothorax (81.3%). The development of pneumothorax was significantly associated with poor prognosis (HR 22.0; p < 0.010). Furthermore, a lower body mass index, greater extent of reticular abnormalities on HRCT, and administration of methylprednisolone pulse therapy were significantly associated with the development of pneumothorax.

Conclusion: Pneumothorax is a serious complication in the clinical course of patients with CTD-ILD and the onset of pneumothorax predicts a poor outcome.

MeSH terms

  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Connective Tissue Diseases / complications
  • Connective Tissue Diseases / diagnosis*
  • Connective Tissue Diseases / drug therapy
  • Connective Tissue Diseases / mortality
  • Female
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Lung Diseases, Interstitial / complications
  • Lung Diseases, Interstitial / diagnosis*
  • Lung Diseases, Interstitial / drug therapy
  • Lung Diseases, Interstitial / mortality
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Pneumothorax / complications
  • Pneumothorax / diagnosis*
  • Pneumothorax / epidemiology
  • Prognosis
  • Proportional Hazards Models
  • Respiratory Function Tests
  • Retrospective Studies
  • Risk Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vital Capacity

Substances

  • Anti-Inflammatory Agents
  • Methylprednisolone

Grants and funding

The authors received no specific funding for this work.